Atrasentan for hormone refractory prostate cancer
Status Suspended
Process STA pre-2018
Referral date 01 June 2004
Topic area
  • Cancer
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
27 May 2005 Topic summary published
25 August 2006 This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme.
8 January 2007 Topic is suspended as the manufacturer has not applied for EMEA regulatory approval at this time

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance